Basel Medical Group (BMGL) appoints Darren Tan as Chief Commercial Officer

Rhea-AI Filing Summary

Basel Medical Group Ltd announced that its Board of Directors has appointed Mr. Tan Boon Chye (Darren) as Chief Commercial Officer, effective August 15, 2025. He brings experience in business consulting, marketing, financing, and corporate development, having started his entrepreneurial career in 2007 and co-founded multiple companies across different industries.

Mr. Darren Tan holds a BSc in Accounting & Finance from the University of London and has received the 2010 Successful Entrepreneur Award (Platinum Category) and the 2011 SME1 Asia Emerging Award. He is an equity interest holder in Basel Medical Fund, a subfund of Rainforest Capital VCC, which is the majority and controlling shareholder of the company. The company states that there is no family relationship between him and any other director or executive officer.

Insights

Corporate governance analyst

Basel Medical adds a Chief Commercial Officer with ties to its controlling shareholder.

The company has appointed Darren Tan as Chief Commercial Officer effective August 15, 2025. His background spans entrepreneurship, marketing, financing, and corporate development, which may support Basel Medical Group’s commercial strategy as it develops and markets its offerings. The filing highlights his prior awards and media recognition, underscoring external validation of his business track record.

The disclosure also notes that he holds an equity interest in Basel Medical Fund, a subfund of Rainforest Capital VCC, identified as the majority and controlling shareholder of the company. This links a key executive to the controlling owner, which can concentrate influence but is explicitly disclosed for transparency. The company further states that there are no family relationships between him and other directors or executive officers, addressing a common governance concern about related-party ties.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-42527

Basel Medical Group Ltd

6 Napier Road,

Unit #02-10/11 Gleneagles Medical Centre

Singapore 258499

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Appointment of Chief Commercial Officer

The Board of Directors of Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) has appointed Mr. Tan Boon Chye (Darren) as its Chief Commercial Officer effective August 15, 2025.

Mr. Darren Tan began his entrepreneurial journey in 2007 with a marketing venture. With extensive experience in business consulting, marketing, financing, and corporate development, he has a proven track record in business. A graduate of the University of London (BSc Accounting & Finance), Darren has also co-founded multiple companies across diverse industries. His achievements have been recognized with the 2010 Successful Entrepreneur Award (Platinum Category) and the 2011 SME1 Asia Emerging Award, and he has been featured by Global Business Magazine, Channel News Asia, and Phoenix Satellite TV.

Mr. Darren Tan is an equity interest holder in Basel Medical Fund, a subfund of Rainforest Capital VCC, which is the majority and controlling shareholder of the Company. No family relationship exists between Mr. Darren Tan and any other director or executive officer of the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Basel Medical Group Ltd
	By:	/s/ Darren Yen Feng Chhoa
	Name:	Dr. Darren Yen Feng Chhoa
	Title:	Chief Executive Officer
Date: August 21, 2025

FAQ

What did Basel Medical Group Ltd (BMGL) announce in this Form 6-K?

Basel Medical Group Ltd reported that its Board of Directors appointed Mr. Tan Boon Chye (Darren) as the company’s Chief Commercial Officer, effective August 15, 2025.

Who is the new Chief Commercial Officer of Basel Medical Group Ltd (BMGL)?

The new Chief Commercial Officer is Mr. Tan Boon Chye (Darren), an entrepreneur with experience in business consulting, marketing, financing, and corporate development who began his entrepreneurial journey in 2007.

What is the educational and professional background of Darren Tan at BMGL?

Darren Tan holds a BSc in Accounting & Finance from the University of London, has co-founded multiple companies across diverse industries, and has been recognized with the 2010 Successful Entrepreneur Award (Platinum Category) and the 2011 SME1 Asia Emerging Award.

Does the new CCO of BMGL have any ownership connection to the company’s controlling shareholder?

Yes. The filing states that Darren Tan is an equity interest holder in Basel Medical Fund, a subfund of Rainforest Capital VCC, which is described as the majority and controlling shareholder of Basel Medical Group Ltd.

Are there any family relationships between Darren Tan and other Basel Medical Group executives or directors?

The company states that no family relationship exists between Darren Tan and any other director or executive officer of Basel Medical Group Ltd.

Which executive signed the Form 6-K for Basel Medical Group Ltd (BMGL)?

The report was signed on behalf of Basel Medical Group Ltd by Dr. Darren Yen Feng Chhoa, who is identified as the company’s Chief Executive Officer, dated August 21, 2025.